The latest update is out from Biophytis SA ( (FR:ALBPS) ).
Biophytis announced its participation in the BIO-Europe Spring conference in Milan, where it aims to engage with industry leaders and partners to discuss the future of its main drug candidate, BIO101, particularly in the areas of obesity and sarcopenia. This participation underscores Biophytis’s commitment to advancing its position in the biotechnology industry, focusing on age-related diseases, and potentially strengthening its stakeholder relationships and market presence.
More about Biophytis SA
Biophytis SA is a clinical-stage biotechnology company that focuses on developing drug candidates for age-related diseases. Their primary product, BIO101, is being developed for muscular diseases such as sarcopenia and Duchenne muscular dystrophy, respiratory diseases like Covid-19, and metabolic diseases including obesity. The company is headquartered in Paris, France, with subsidiaries in Cambridge, Massachusetts, USA, and Brazil, and its shares are listed on Euronext Growth Paris and the OTC market.
YTD Price Performance: -19.14%
Average Trading Volume: 7,225
Technical Sentiment Consensus Rating: Buy
Current Market Cap: €4.39M
See more data about ALBPS stock on TipRanks’ Stock Analysis page.
Trending Articles:
Questions or Comments about the article? Write to editor@tipranks.com